XIAN, China, Nov. 21, 2026 /PRNewswire/ — Bon Natural Life Limited (NASDAQ: BON) ("BON" or the "Company"), a leading provider of bio-ingredient solutions for the natural, health, and personal care industries, today announced that its subsidiary, Xi’an App-Chem Bio (Tech) Co., Ltd. ("App-Chem") recently convened a symposium with China Oat Group Co., Ltd. ("China Oat Group") on the theme of "Advancing the High-Quality Development of China’s Health Industry". At the event, the two parties announced the establishment of the BON Natural Ingredients and Biomanufacturing Joint Laboratory (the "BON Joint Lab" or the "Joint Lab").
Through an innovative collaboration model, the BON Joint Lab aims to build an integrated innovation framework spanning the entire value chain, from fundamental research and pilot-scale development to standard-setting and industrial commercialization. The Joint Lab will focus on developing an AI-driven technological platform for the biomanufacturing of natural ingredients, with synthetic biology serving as its technological foundation and artificial intelligence (AI) as a key competitive differentiator. Its primary focus will be the development of biomanufacturing technologies for high-value natural ingredients. This integrated technological framework is expected to enhance the Joint Lab’s competitive position in the natural ingredients biomanufacturing sector while offering the industry new alternatives to conventional production methods.
Oats are widely recognized for their nutritional value and health benefits. They contain bioactive compounds such as beta-glucan and avenanthramides (AVAs), which have demonstrated various biological activities, including cardiovascular protection, blood glucose regulation, antioxidant effects, and anti-inflammatory properties. As a supplier of oat-based health products, China Oat Group serves a market characterized by strong demand and significant growth potential. However, limited availability of natural raw materials and high sourcing costs have constrained the broader commercial application and market expansion of oat-derived products.
Through the establishment of the Joint Lab, BON and China Oat Group aim to develop biomanufacturing technologies for oat-derived natural ingredients, with the goal of fundamentally addressing challenges related to supply availability, supply stability, and high production costs. BON and China Oat Group believe that this initiative is of significant importance in expanding the market for oat-derived natural ingredients.
Standards development plays a critical role in the biomanufacturing of natural ingredients. The unique complexity of natural ingredient sourcing, heightened regulatory scrutiny of product safety, and distinct consumer preferences for naturally derived ingredients make the establishment of standards for biomanufactured natural ingredients critically important to their commercial value.
BON and China Oat Group have undertaken extensive and productive work in developing quality standards for natural ingredients. The Joint Lab will make standards development a dedicated area of focus, conducting systematic testing and validation of key parameters, including ingredient purity, safety, and elemental and isotopic profiles. Through a comprehensive and integrated process of evaluation and optimization, the Joint Lab aims to establish systematic differentiation in product standards across multiple dimensions, including safety, differentiated quality standards, and similarity to naturally derived counterparts.
BON has established a strong presence in the natural ingredients biomanufacturing sector and has articulated its vision of becoming an "AI-driven pioneer in digital nutrition". The Company is committed to accelerating the transition from conventional natural extraction methods to AI-driven biomanufacturing. The Company believes that it has built a strong technological foundation in natural products, biosynthesis, and the application of AI in biology, supported by robust industrialization capabilities and global market development expertise.
China Oat Group has developed extensive expertise across the entire oat value chain and holds more than ten invention patents in China, along with multiple patents in the United States, Europe, Canada, Australia, and other markets. Leveraging its advanced technologies in areas such as oat protein enzymatic hydrolysis and the preservation of beta-glucan bioactivity, China Oat Group has developed a portfolio of oat-based nutritional products whose health benefits have been evaluated through medical research. China Oat Group was also among the first companies to achieve large-scale, standardized deep processing of oats, with its related technologies receiving authoritative certifications in Europe and the United States.
Mr. Yongwei Hu, Chairman of BON, commented, "Our strategic collaboration with China Oat Group marks a pivotal step in our efforts to establish a stronger presence in the core natural ingredients sector, accelerate our expansion into the rapidly growing global biomanufacturing market, and further strengthen our position as an innovation leader in the industry. Through the Joint Lab, we aim to advance cutting-edge research in areas such as the biosynthesis of high-value natural ingredients, the discovery of functional bioactive compounds, and precision nutrition interventions. We are committed to accelerating the commercialization of scientific and technological innovations and delivering a broader range of safe and effective health solutions to consumers. Through the disciplined execution of our technology-driven business strategy, we seek to unlock significant commercial value and generate sustainable returns for our investors."
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company’s website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
| This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |
Read the original article : BON Unveils Joint Lab for Natural Ingredients & Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation

